Pre-Open Stock Movers 03/30: (MBRX) (ABCL) (SEEL) Higher; (WVE) (BFLY) (CLDX) Lower (more...)

Pre-Open Stock Stock Movers

Wave Life Sciences Ltd. (Nasdaq: WVE) 24.8% LOWER; announced data from the Phase 1b/2a PRECISION-HD2 and PRECISION-HD1 trials evaluating investigational treatments WVE-120102 and WVE-120101, respectively, in Huntingtons disease (HD). In the PRECISION-HD2 core trial, results from all participants (n=88) showed no statistically significant change in mutant huntingtin protein (mHTT) versus placebo after single or multiple doses of WVE-120102 up to and including 32 mg monthly. There was no evidence of a dose response across the dose levels tested.

Moleculin Biotech, Inc., (Nasdaq: MBRX) 21.4% HIGHER; announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of soft tissue sarcoma (STS) lung metastases.

AbCellera (NASDAQ: ABCL) 13.6% HIGHER; total revenue of $233 million1 in 2020, up 1,908% year-over-year

Novan (NASDAQ: NOVN) 8% HIGHER; President and CEO, Paula Stafford, bought 70,000 shares on 03/26 at $1.43.

Seelos Therapeutics (NASDAQ: SEEL) 7.5% HIGHER; B.Riley initiates coverage with a Buy rating and a price target of $15.00.

Butterfly Network, Inc. (NYSE: BFLY) 6.7% LOWER; Reported 2020 revenues of $46.3 million compared to $27.6 million in 2019, a year-over-year increase of 68%.

Vipshop Holdings Limited (NYSE: VIPS) 6.1% HIGHER; announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$500 million of its Class A ordinary shares over the 24-month period upon the establishment of share repurchase program. The Company plans to adopt and implement such share repurchase program in accordance with applicable rules and requirements under the Securities Exchange Act of 1934, as amended, and the Company's insider trading policy.

Celldex Therapeutics, Inc. (NASDAQ: CLDX) 5% LOWER; reports fourth-quarter results.

Yelp (NYSE: YELP) 4.7% HIGHER; Citi upgraded from Neutral to Buy with a price target of $48.00 (from $33.00).

PAVmed (NASDAQ: PAVM) 3.8% HIGHER; Cantor Fitzgerald initiates coverage with an Overweight rating and a price target of $8.00.

Aytu Biosciences (NASDAQ: AYTU) 2.9% HIGHER; Cantor Fitzgerald initiates coverage with an Overweight rating and a price target of $11.00.

Roku (NASDAQ: ROKU) 1.4% HIGHER; Truist analyst upgraded from Hold to Buy after the recent pullback in the price action yielded a more attractive valuation.

You May Also Be Interested In

• Snap (SNAP), Meta (META) gain as House orders sale or ban of TikTok
• Baird Defends Cardinal Health (CAH): 'Market fears played out, buyers on weakness'
• IT services stocks fall following Infosys' numbers